← Back to Search

Device

CanGaroo Envelope for Cardiac Arrhythmias

N/A
Waitlist Available
Led By Thomas F. Deering, MD
Research Sponsored by Aziyo Biologics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post-procedure
Awards & highlights

Summary

A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post-procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Association between CanGaroo envelope use and CIED implant-related outcomes and events.
Association between participant characteristics and outcomes

Trial Design

2Treatment groups
Experimental Treatment
Group I: No EnvelopeExperimental Treatment0 Interventions
Participants who do not receive an envelope of any kind during their CIED implant.
Group II: CanGaroo EnvelopeExperimental Treatment1 Intervention
Participants who receive a CanGaroo envelope during their CIED implant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CanGaroo Envelope
2020
N/A
~600

Find a Location

Who is running the clinical trial?

Aziyo Biologics, Inc.Lead Sponsor
12 Previous Clinical Trials
4,113 Total Patients Enrolled
Thomas F. Deering, MDPrincipal InvestigatorPiedmont Heart Institute
~201 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top